Drug Trial Radar · NCT05267899
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 1, 2022
Primary completion
Oct 15, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Zhejiang Haichang Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how safe and tolerable the study drug is for patients with solid tumors. The study is also done to learn how the study drug is taken up by your body; this is called Pharmacokinetic (PK) studies and how the study drug affects the body; this is called Pharmacodynamics (PD)
Conditions
- Advanced Solid Tumors
Interventions
WGI-0301Drug
WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: Approximately 16 months
- Recommended Phase 2 Dose of WGI-0301Time frame: Approximately 16 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
The Oncology Institute of Hope and Innovation
Whittier, California · Recruiting
University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.